Goldman Sachs
SRNE

Goldman Sachs’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Goldman Sachs’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000,100
Closed -$6.83M – 6447
2020
Q4 		$6.83M Buy
+1,000,100
New +$8.03M ﹤0.01% 2760
2018
Q1 		– Sell
-1,100
Closed -$4K – 6500
2017
Q4 		$4K Sell
1,100
-2,200
-67% -$5.73K ﹤0.01% 6266
2017
Q3 		$6K Sell
3,300
-1,100
-25% -$2.02K ﹤0.01% 6567
2017
Q2 		$9K Sell
4,400
-1,100
-20% -$2.15K ﹤0.01% 6660
2017
Q1 		$22K Buy
5,500
+2,200
+67% +$11K ﹤0.01% 6495
2016
Q4 		$16K Buy
3,300
+2,100
+175% +$12.6K ﹤0.01% 6699
2016
Q3 		$9K Buy
+1,200
New +$8.08K ﹤0.01% 6888
2016
Q2 		– Sell
-1,100
Closed -$6K – 7320
2016
Q1 		$6K Sell
1,100
-1,500
-58% -$8.72K ﹤0.01% 6965
2015
Q4 		$23K Sell
2,600
-178,100
-99% -$1.5M ﹤0.01% 6816
2015
Q3 		$1.52M Buy
180,700
+179,300
+12,807% +$2.86M ﹤0.01% 4072
2015
Q2 		$25K Buy
+1,400
New +$18K ﹤0.01% 7045

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Goldman Sachs's SRNE Position: Q1 2023 in Review

Goldman Sachs sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 2,773,811 shares — an estimated $2.46M sold.

Goldman Sachs first reported a position in SRNE in Q2 2014 and held it in 33 quarters. The position peaked at $13.1M in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Goldman Sachs reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 2,773,811 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $2.46M.
  • Goldman Sachs first reported a position in Sorrento Therapeutics, Inc. in Q2 2014 and held it in 33 quarters.
  • Goldman Sachs's Sorrento Therapeutics, Inc. position peaked at $13.1M in Q3 2020.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.